CTI BioPharma (CTIC) Sees Unusually-High Trading Volume

CTI BioPharma Corp (NASDAQ:CTIC) shares saw strong trading volume on Friday . 5,420,700 shares changed hands during mid-day trading, an increase of 1,301% from the previous session’s volume of 386,918 shares.The stock last traded at $5.08 and had previously closed at $4.90.

Several analysts have recently commented on the company. BidaskClub raised CTI BioPharma from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 16th. ValuEngine raised CTI BioPharma from a “sell” rating to a “hold” rating in a research report on Saturday, June 2nd. JMP Securities assumed coverage on CTI BioPharma in a research report on Wednesday, March 7th. They issued an “outperform” rating and a $8.00 target price for the company. Cann reaffirmed a “buy” rating and issued a $5.00 target price on shares of CTI BioPharma in a research report on Wednesday, March 7th. Finally, Zacks Investment Research raised CTI BioPharma from a “sell” rating to a “hold” rating in a research report on Wednesday, April 25th. Two research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. CTI BioPharma has an average rating of “Buy” and a consensus price target of $6.42.

The company has a debt-to-equity ratio of 0.17, a quick ratio of 5.30 and a current ratio of 5.32.



CTI BioPharma (NASDAQ:CTIC) last released its quarterly earnings data on Thursday, May 3rd. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.02. The firm had revenue of $10.48 million during the quarter, compared to analysts’ expectations of $10.30 million. CTI BioPharma had a negative return on equity of 63.27% and a negative net margin of 71.30%. equities research analysts predict that CTI BioPharma Corp will post -0.95 EPS for the current fiscal year.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. NEA Management Company LLC acquired a new stake in CTI BioPharma during the first quarter valued at $14,625,000. Franklin Resources Inc. acquired a new stake in CTI BioPharma during the first quarter valued at $13,542,000. Stonepine Capital Management LLC boosted its position in CTI BioPharma by 84.8% during the fourth quarter. Stonepine Capital Management LLC now owns 1,834,838 shares of the biopharmaceutical company’s stock valued at $4,917,000 after purchasing an additional 841,838 shares during the last quarter. Millennium Management LLC acquired a new stake in CTI BioPharma during the first quarter valued at $3,068,000. Finally, Renaissance Technologies LLC boosted its position in CTI BioPharma by 48.3% during the fourth quarter. Renaissance Technologies LLC now owns 609,849 shares of the biopharmaceutical company’s stock valued at $1,634,000 after purchasing an additional 198,700 shares during the last quarter. 62.78% of the stock is owned by hedge funds and other institutional investors.

CTI BioPharma Company Profile

CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. It develops PIXUVRI, a novel aza-anthracenedione for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma; and pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase III clinical trials for the treatment of adult patients with myelofibrosis.

Receive News & Ratings for CTI BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CTI BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply